Adial Pharmaceuticals Financials
| ADIL Stock | USD 0.74 0.02 2.78% |
Adial |
Understanding current and past Adial Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adial Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Adial Pharmaceuticals' assets may result in an increase in income on the income statement.
Adial Pharmaceuticals Stock Summary
Adial Pharmaceuticals competes with Transcode Therapeutics, Aditxt, Reviva Pharmaceuticals, Avenue Therapeutics, and Benitec Biopharma. Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US00688A1060 |
| CUSIP | 00688A106 00688A205 |
| Location | Virginia; U.S.A |
| Business Address | 4870 Sadler Road, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.adial.com |
| Phone | 804 487 8196 |
| Currency | USD - US Dollar |
Adial Pharmaceuticals Key Financial Ratios
| Return On Equity | -3.24 | ||||
| Return On Asset | -1.06 | ||||
| Target Price | 6.5 | ||||
| Beta | 1.13 |
Adial Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Adial Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Adial Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adial Pharmaceuticals competition to find correlations between indicators driving Adial Pharmaceuticals's intrinsic value. More Info.Adial Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Adial Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Adial Pharmaceuticals Systematic Risk
Adial Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Adial Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Adial Pharmaceuticals correlated with the market. If Beta is less than 0 Adial Pharmaceuticals generally moves in the opposite direction as compared to the market. If Adial Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adial Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adial Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Adial Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Adial Pharmaceuticals March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adial Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adial Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adial Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Adial Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adial Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 31.98 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 5.8 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.